Biography

Dr. Chen Jing, PhD obtained from University of Hong Kong, is a health services researcher with extensive research experience across academia, government, and healthcare industry. Her research focuses on economic evaluation and innovative health service models to improve chronic disease management and guide public health policy. Her earlier studies on DAAs for HCV and HCV/HBV coinfection informed shortened treatment regimens, led to the FDA black box warning on HBV reactivation, and supported the inclusion of HCV therapies in China’s reimbursement list. Currently joining CUHK, Dr. Chen is an active member of APASL Viral Elimination Taskforce and a leading author of the upcoming CHB clinical practice guidelines. Her current work includes economic evaluation of decentralized HBV management in Hong Kong primary care (GRF funded) and developing high-tech–assisted service models, including AI-supported systems (HKSTP funded) and robotics-assisted chronic disease assessment (CUHK Direct Grant funded). In recognition of her contributions to public health research for liver disease, Dr. Chen received the 2025 Rising Star Award from APASL.